ID27933A - Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker - Google Patents

Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker

Info

Publication number
ID27933A
ID27933A IDW20002583A ID20002583A ID27933A ID 27933 A ID27933 A ID 27933A ID W20002583 A IDW20002583 A ID W20002583A ID 20002583 A ID20002583 A ID 20002583A ID 27933 A ID27933 A ID 27933A
Authority
ID
Indonesia
Prior art keywords
reducture
farnesiltrans
ferase
hmg
coa
Prior art date
Application number
IDW20002583A
Other languages
English (en)
Indonesian (id)
Inventor
Judith Leopold
Roger Schofield
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ID27933A publication Critical patent/ID27933A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW20002583A 1998-05-12 1999-05-10 Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker ID27933A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8520298P 1998-05-12 1998-05-12
US9225398P 1998-07-10 1998-07-10

Publications (1)

Publication Number Publication Date
ID27933A true ID27933A (id) 2001-05-03

Family

ID=26772425

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002583A ID27933A (id) 1998-05-12 1999-05-10 Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker

Country Status (25)

Country Link
US (1) US6492410B1 (is)
EP (1) EP1077949A2 (is)
JP (1) JP2002514628A (is)
KR (1) KR20010043529A (is)
CN (1) CN1171874C (is)
AP (1) AP2000001984A0 (is)
AU (1) AU758891B2 (is)
BG (1) BG105003A (is)
BR (1) BR9911785A (is)
CA (1) CA2331295A1 (is)
EA (1) EA003860B1 (is)
EE (1) EE200000660A (is)
GE (1) GEP20032996B (is)
HR (1) HRP20000771A2 (is)
HU (1) HUP0102322A3 (is)
ID (1) ID27933A (is)
IL (1) IL139502A0 (is)
IS (1) IS5713A (is)
NO (1) NO20005680L (is)
NZ (1) NZ508357A (is)
OA (1) OA11551A (is)
PL (1) PL344662A1 (is)
SK (1) SK16742000A3 (is)
WO (1) WO1999058505A2 (is)
YU (1) YU68900A (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363088A1 (en) * 1999-02-11 2000-08-17 Patrick T. Prendergast Methods for treating viral infections
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US20020132781A1 (en) * 2000-10-06 2002-09-19 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
WO2005042710A1 (en) * 2003-10-28 2005-05-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of statin to kill ebv-transformed b cells
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
KR100930365B1 (ko) * 2006-11-09 2009-12-08 덕성여자대학교 산학협력단 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물
US20080119444A1 (en) * 2006-11-16 2008-05-22 Steven Lehrer Methods and compositions for the treatment of cancer
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
NL9002031A (nl) 1990-09-14 1992-04-01 Voskuilen Woudenberg Bv Inrichting voor het bewerken van een uitwendig buisoppervlak.
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
KR19990028303A (ko) * 1995-06-22 1999-04-15 한센 핀 베네드, 안네 제헤르 성장호르몬 방출 특성을 가지는 화합물
JPH11508262A (ja) 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
UA57081C2 (uk) * 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування

Also Published As

Publication number Publication date
EA003860B1 (ru) 2003-10-30
NO20005680D0 (no) 2000-11-10
HRP20000771A2 (en) 2001-06-30
CN1171874C (zh) 2004-10-20
NO20005680L (no) 2001-01-10
AU3979299A (en) 1999-11-29
YU68900A (sh) 2002-12-10
IL139502A0 (en) 2001-11-25
OA11551A (en) 2004-05-24
PL344662A1 (en) 2001-11-19
WO1999058505A3 (en) 2000-01-06
SK16742000A3 (sk) 2001-07-10
JP2002514628A (ja) 2002-05-21
WO1999058505A2 (en) 1999-11-18
BG105003A (en) 2001-07-31
AU758891B2 (en) 2003-04-03
BR9911785A (pt) 2001-04-03
EA200001164A1 (ru) 2001-06-25
HUP0102322A2 (hu) 2001-11-28
US6492410B1 (en) 2002-12-10
IS5713A (is) 2000-11-10
GEP20032996B (en) 2003-06-25
EP1077949A2 (en) 2001-02-28
HUP0102322A3 (en) 2001-12-28
EE200000660A (et) 2002-04-15
NZ508357A (en) 2002-09-27
CN1306515A (zh) 2001-08-01
CA2331295A1 (en) 1999-11-18
AP2000001984A0 (en) 2000-12-31
KR20010043529A (ko) 2001-05-25
HK1038355A1 (en) 2002-03-15

Similar Documents

Publication Publication Date Title
ID27394A (id) Kombinasi farmasi yang mengandung inhibitor cox-2 dan inhibitor inos
ID30139A (id) Kompleks dari inhibitor ras-farnesiltransferase dan sulfobutileter-7- -siklodekstrin atau 2-hidroksipropil- -siklodekstrin dan metodanya
EE200000488A (et) Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
CY2018023I2 (el) Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης
NO20004550D0 (no) Enzyminhibitorer
NO20004220L (no) Inhibitorer av fosfolipaseenzymer
NO20000487D0 (no) Substituerte quinazolinderivater og anvendelse derav som tyrosin kinase inhibitorer
DZ3223A1 (fr) Inhibiteurs de tyrosine kinases
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
FI965019A7 (fi) Entsyymi-inhibiittoreita
ID30322A (id) HETEROSIKLIK YANG MENGANDUNG INHIBITOR BIFENIL aP2 DAN METODANYA
EE9900006A (et) Uued amidinoderivaadid ja nende kasutamine trombiini inhibiitoritena
ID22650A (id) Penggunaan penghambat-penghambat lipase usus lambung
ID27192A (id) Sulfonamida trisiklik dan turunannya sebagai inhibitor metaloproteinase matriks
ID22956A (id) Sintesa disulfida dan polisulfida organik
NO20001979L (no) Anvendelse av inhibitorer av renin-angiotensin-systemet
PT927183E (pt) Inibidores espirociclicos de metaloproteases
NO20000475L (no) Korrosjonsinhibitorsammensetninger, fremgangsmÕte for anvendelse samt fremgangsmÕte for fremstilling av disse
FR2816843B1 (fr) Inhibiteurs de l'enzyme 5 alpha-reductase
DE60038350D1 (de) Angiotensin-Converting-Enzyme-Hemmer
EE200000660A (et) Valk farnesüültransferaasi ja HMG CoA reduktaasi inhibiitorite kombinatsioonid ja nende kasutamine vähi raviks
ID23014A (id) INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER
EE200100046A (et) ACAT ja MMP inhibiitorite koosmanustamine aterosklerootiliste kahjustuste raviks
FI973929A0 (fi) WOF inhibitor